Not all types of diabetes carries the same risk for the brain
A sweeping study of 1.3 million South Korean adults has revealed that the way diabetes is treated may shape not only the body's future, but the mind's. Presented at the European Congress of Endocrinology in Prague, the research found that insulin-dependent diabetics face more than twice the dementia risk of those without the condition — a disparity that points to glucose instability, not diabetes alone, as a potential architect of cognitive decline. The findings invite medicine to reconsider what it means to manage a chronic illness, suggesting that protecting the brain may require the same vigilance long devoted to protecting the heart.
- Insulin-dependent diabetics face 2.1 to 2.4 times the dementia risk of non-diabetics — a gap so sharp it suggests treatment type, not diagnosis alone, is driving cognitive vulnerability.
- Recurrent hypoglycemic episodes and wild glucose swings in insulin-treated patients may be quietly eroding brain tissue in ways that oral medications largely avoid.
- The disparity unsettles a common assumption: that all diabetes poses roughly equal neurological risk, when in fact the intensity of treatment appears to be a critical variable.
- Researchers are now pushing toward continuous glucose monitoring as a potential shield — real-time blood sugar stabilization reframed as a tool for preserving cognitive independence.
- For millions of insulin-dependent patients worldwide, the study redraws the stakes of daily disease management, placing dementia prevention alongside heart and kidney protection as a primary goal.
A study tracking more than 1.3 million South Korean adults over more than a decade has produced a finding that may reshape how the medical world thinks about diabetes and the brain. Presented at the 28th European Congress of Endocrinology in Prague, the research revealed that not all diabetes carries equal cognitive risk — and that the type of treatment a patient receives may matter as much as the diagnosis itself.
Researchers from Kyung Hee University Hospital at Gangdong and Samsung Medical Center followed adults aged 40 and older from 2013 through 2024, dividing them into four groups based on diabetes status and treatment. Those taking oral medications for type 2 diabetes showed a modest 1.3-fold increase in dementia risk compared to non-diabetics. But the picture darkened considerably for insulin users: those with insulin-treated type 2 diabetes faced 2.1 times the risk, while those with type 1 diabetes faced 2.4 times the risk. The elevated rates held when researchers examined Alzheimer's disease and vascular dementia separately.
Lead author Professor Ji Eun Jun described the findings as surprising, noting that they challenge the assumption that diabetes poses a uniform neurological threat. The working hypothesis centers on glucose instability — the recurrent low blood sugar episodes and wider fluctuations that insulin therapy often produces. These swings, researchers believe, may damage the brain in ways that steadier, orally managed glucose levels do not.
The practical implications are already coming into focus. Continuous glucose monitoring — which tracks blood sugar in real time — could shift from optional to standard care for insulin-dependent patients. Earlier and more frequent cognitive screening may follow. The study does not yet prove that tighter glucose control prevents dementia, but it opens that possibility, and the next phase of research will test whether stabilizing blood sugar can slow or reverse the brain's decline.
A study of more than 1.3 million South Korean adults has found that people who depend on insulin to manage their diabetes face a substantially elevated risk of developing dementia—roughly two and a half times higher than those without diabetes. The research, presented at the 28th European Congress of Endocrinology in Prague, suggests that not all diabetes carries equal cognitive risk. The type of treatment matters, and how the body's glucose is managed may shape the brain's future.
Researchers from Kyung Hee University Hospital at Gangdong and Samsung Medical Center tracked adults aged 40 and older from 2013 through 2024, sorting them into four groups: those without diabetes, those taking oral medications for type 2 diabetes, those using insulin for type 2 diabetes, and those with type 1 diabetes. Over the study period, they documented who developed dementia and compared the rates across groups. The pattern that emerged was striking in its specificity. People taking oral diabetes medications were about 1.3 times more likely to develop dementia than those without diabetes. But the risk climbed sharply for insulin users: those with insulin-treated type 2 diabetes showed a 2.1-fold increase in dementia risk, while those with type 1 diabetes faced a 2.4-fold increase. The same elevated risk appeared when researchers looked specifically at Alzheimer's disease and vascular dementia separately.
Professor Ji Eun Jun, the study's lead author, emphasized that the findings challenge a common assumption about diabetes and brain health. "This is surprising because it suggests that not all types of diabetes carries the same risk, and that people with more intensive or insulin-dependent treatment may be particularly vulnerable to cognitive decline," he said. The implication is that diabetes is not simply a metabolic condition—it is also a potential threat to cognitive function, and the intensity of treatment appears to correlate with that threat.
The researchers have a working hypothesis about why insulin-dependent patients face such elevated risk. They point to recurrent episodes of low blood sugar and the larger swings in glucose levels that often accompany insulin therapy. These fluctuations may damage the brain in ways that oral medications do not. If that mechanism is correct, then stabilizing glucose levels—keeping blood sugar steadier over time—might help protect cognitive function. Professor Jun noted that the team is planning further studies to test this theory and to identify which patients are most vulnerable.
The practical implications are beginning to take shape. If insulin-dependent diabetes truly carries this much higher dementia risk, then routine diabetes care may need to evolve. Continuous glucose monitoring, which tracks blood sugar in real time and can help patients and doctors keep levels more stable, could become standard practice rather than optional. Patients on insulin might benefit from earlier and more frequent screening for cognitive decline, catching problems before they advance. The goal would be to identify high-risk individuals sooner and to test whether tighter glucose control can actually prevent dementia from developing in the first place.
For the millions of people worldwide who depend on insulin to survive, the findings carry weight. They suggest that managing diabetes is not only about preventing heart disease or kidney damage—it is also about protecting the mind. The study does not yet prove that better glucose control will prevent dementia, but it opens a door to that possibility. The next phase of research will determine whether stabilizing blood sugar can slow or stop cognitive decline, and whether the brain's vulnerability to insulin-dependent diabetes is reversible.
Citas Notables
Not all types of diabetes carries the same risk, and people with more intensive or insulin-dependent treatment may be particularly vulnerable to cognitive decline— Professor Ji Eun Jun, Kyung Hee University Hospital at Gangdong
Recognising diabetes as a potential risk factor for brain health and not just a metabolic condition could help identify patients who may benefit from earlier monitoring for cognitive decline— Professor Ji Eun Jun
La Conversación del Hearth Otra perspectiva de la historia
Why does insulin treatment seem to carry more dementia risk than oral medications? Are insulin users sicker to begin with?
That's the first question everyone asks. The study controlled for that—they were comparing people at similar disease stages. The difference appears to be the treatment itself, not the underlying severity. Insulin is more powerful but also more volatile. It can swing blood sugar up and down more dramatically.
So it's the swings themselves that damage the brain?
That's the leading theory. Recurrent low blood sugar episodes and large glucose fluctuations may injure brain cells over time. Oral medications tend to work more gently and steadily. The brain seems to prefer stability.
Can this be reversed? If someone's been on insulin for years, is their dementia risk locked in?
We don't know yet. That's exactly what the researchers want to study next. If they can show that tighter glucose control actually prevents dementia, then the answer might be yes—it's preventable, maybe even reversible.
What would tighter glucose control look like in practice?
Continuous glucose monitors that track blood sugar minute by minute, adjusted insulin dosing, maybe different insulin regimens. The goal is to keep glucose in a narrower, steadier range instead of the peaks and valleys that happen now.
How many people are we talking about?
Millions globally depend on insulin. If this risk is real, it's a massive public health issue. That's why the study matters—it's not just a statistical finding. It's a signal that we may be missing something important in how we treat diabetes.